TABLE 1

Outcome Values for Each Subject at Baseline and 2–4 Hours After Physostigmine Injection

fp at baselinefp before physostigminefp after physostigmine*fp at end of studyVT/fp at baselineVT/fp after physostigmine*BPf at baselineBPf after physostigmine*
Subject no.ThalCBCortStrThalCBCortStrThalCBCortStrThalCBCortStr
132.6%37.0%36.4%39.2%151.073.954.077.8140.964.749.471.9131.654.534.658.4121.545.330.052.5
237.0%36.1%36.5%37.5%131.425.251.370.9102.920.038.456.9112.05.831.951.583.50.619.037.5
335.9%34.7%32.9%28.6%129.940.351.369.0111.533.042.056.9110.520.931.949.692.113.622.637.5
425.8%25.0%25.9%34.2%180.575.864.993.1140.258.048.174.1161.156.445.573.7120.838.628.754.7
533.7%37.4%44.3%47.3%125.469.449.468.581.549.634.451.7106.050.030.049.162.130.215.032.3
636.6%35.4%39.3%111.155.640.965.1111.055.440.067.891.736.221.545.791.636.020.648.4
Mean33.6%34.3%35.9%37.4%138.256.752.074.1114.746.842.063.2118.837.332.654.795.327.422.643.8
SD4.17%4.65%6.19%6.87%24.420.47.810.2222.817.05.89.224.420.47.810.222.817.05.89.2
  • * Value at 2–4 h after physostigmine administration, at time of greatest displacement of radioligand by acetylcholine.

  • CB = cerebellum; Cort = mean cortex; Str = striatum; Thal = thalamus.

  • Final blood sample could not be drawn for subject 6.